Biotech Volatile Stocks: Geron Corporation (NASDAQ:GERN), Novavax (NASDAQ:NVAX), Aegerion Pharmaceuticals (NASDAQ:AEGR), CytRx Corporation (NASDAQ:CYTR)



Geron Corp. (NASDAQ:GERN) stock had its “positive” rating reiterated by equities research analysts at Wells Fargo & Co. in a research note issued to investors on Thursday, American Banking News.com reports.Geron Corporation (NASDAQ:GERN) stock performance was -2.73% in last session and finished the day at $1.78. Traded volume was 7,214,860 million shares in the last session and the average volume of the stock remained 5.57 million shares. The beta of the stock remained 1.82. Geron Corporation (NASDAQ:GERN) insider ownership is 0.10%.

Novavax, Inc. (NASDAQ:NVAX) on Mar. 10 reported its financial results for the fourth quarter and year ended December 31, 2013 and announced the initiation of a Phase 1/2 clinical trial of its H7N9 avian influenza VLP vaccine candidate with its proprietary Matrix-M adjuvant. Novavax, Inc. (NASDAQ:NVAX) dropped -2.05 percent to $5.26 yesterday on volume of 4.88 million shares. The intra-day range of the stock was $5.06 to $5.60. Novavax, Inc. (NASDAQ:NVAX) has a market capitalization of $1.10 billion.

Deutsche Bank defended Aegerion Pharmaceuticals (NASDAQ:AEGR), reiterated a buy rating and price target of $115.00. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)’s stock on Mar 17, 2014 reported an increase of 3.24% to the closing price of $54.22. Its fifty two weeks range is $36.89 -$101.00. The total market capitalization recorded $1.59 billion. The overall volume in the last trading session was 2,279,221 million shares. In its share capital, Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has 29.30 million outstanding shares.

CytRx (NASDAQ:CYTR) stock had its “buy” rating restated by research analysts at Aegis in a report released on Monday, AmericanBankingNews.com reports. On Monday, shares of CytRx Corporation (NASDAQ:CYTR) dropped -1.69% to close the day at $4.08. Company return on investment (ROI) is -257.90% and its monthly performance is recorded as -35.03%. CytRx Corporation (NASDAQ:CYTR) quarterly revenue growth is -33.33%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone